About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, November 19th, 2014

The QualityStocks
Daily Stock List


Hydrocarb Energy Corp. (HECC)

SmallCapNetwork, OTCJournal, and Greenbackers reported on Hydrocarb Energy Corp. (HECC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Hydrocarb Energy Corp. is a domestic and international energy exploration and production company. The Company’s worldwide operations include domestic U.S. oil and gas production; international exploration; and UAE (United Arab Emirates) oilfield services. Hydrocarb Energy is targeting major under-explored oil and gas projects in emerging, highly prospective regions of the world. The Company has offices in Houston, Texas; Abu Dhabi, UAE; and Windhoek, Namibia.

Hydrocarb Energy has exploration concessions in Africa and production in Galveston Bay. Regarding its domestic production, Hydrocarb is looking to acquire additional onshore and offshore assets and use these assets to build its international efforts. In its international exploration business, the Company is working to increase the value of its Namibia exploration concession.

Pertaining to its Middle East oil field services business, Hydrocarb Energy is focusing on starting operations of its Abu-Dhabi based oil field services company and obtaining major cash flow from new contracts.

The Company holds diversified domestic and international assets. This includes 4 producing oil fields in Galveston Bay, Texas, as well as an exploration license for a 21,300 kms²/5.3 million acre concession in the Owambo Basin of northern Namibia. The southern half of the Owambo Basin is in Namibia. Its northern portion is in Angola, which is the second largest oil producer in Africa.

Otaiba Hydrocarb (in Abu Dhabi) is Hydrocarb Energy’s Middle East division. Otaiba Hydrocarb is presently negotiating consulting and service contracts, and exploration concessions in the UAE and Iraq.

Last month, Hydrocarb Energy reported 6,000 barrels of oil production during September 2014 from its Galveston Bay, Texas oil and gas assets. This represents an increase of 57 percent from 3,800 barrels of oil production in August 2014. Gas production decreased moderately from roughly 9,617 thousand cubic feet (MCF) in August to 9,000 MCF in September 2014.

Hydrocarb Energy Corp. (HECC), closed Wednesday's trading session at $3.15, up 10.53%, on 16,252 volume with 68 trades. The average volume for the last 60 days is 10,548 and the stock's 52-week low/high is $2.50/$9.25.

Ener-Core, Inc. (ENCR)

PennyStocks24, Greenbackers, TheMicrocapNews, StreetAuthority Financial, StockBlogs, ProfitableTrading, Dividend Opportunities, Investors Alley, and Trade of the Week reported earlier on Ener-Core, Inc. (ENCR), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Ener-Core, Inc. designs and manufactures ground-breaking systems for producing continuous energy from a wide array of sources. This includes previously unusable ultra-low quality gas. The Ener-Core Gradual Oxidizer is the Company’s patented oxidation technology. It enables the conversion of these gases into useful heat and power with the lowest known associated emissions. Ener-Core serves numerous markets around the world. These markets include oil fields, biogas, coal mines, natural gas, emissions control, and utility power generation. The Company has its headquarters in Irvine, California.

Ener-Core offers systems with fuel flexibility and pollution control for power generation, with the Ener-Core Gradual Oxidizer matched to gas turbines. The Gradual Oxidizer can also undergo customization for integration with larger existing power generation systems to offer first-rate pollution control and achieve zero emissions.

The Company has developed the 250kW Ener-Core Powerstation FP250, and its larger counterpart, the 2MW Ener-Core Powerstation KG2-3G/GO, to transform methane gas, especially "ultra-low-Btu gas" from landfills, coal mines, oil fields and other low quality methane sources into continuous clean electricity with near-zero emissions.

The specific engineering of the Powerstations are for fuel flexibility and modularity so that these low-Btu gas sources can be used as an energy resource instead of wasted through venting and/or flaring. The FP250 is a clean power generation solution using the Ener-Core Gradual Oxidation technology integrated with a 250 kW gas turbine.

Today, Ener-Core announced that it entered into a global licensing agreement with the Dresser-Rand Company. This is to develop and market the Dresser-Rand KG2-3GEF two-megawatt gas turbine coupled with the Ener-Core oxidizer.

Mr. Alain Castro, Chief Executive Officer of Ener-Core, said, "The adoption of the Ener-Core oxidizer technology by Dresser-Rand is an important step in capturing the $65 billion waste gas to power opportunity. This commercial license is a great opportunity for Ener-Core to successfully scale up its power generation technology to the 2 MW power capacity.”

Dresser-Rand is amongst the world's largest suppliers of rotating equipment to the oil, gas petrochemical and process industries. The license agreement grants Dresser-Rand exclusive rights to commercialize the Ener-Core 1-4MW MW Gradual Oxidizer bundled with the Dresser-Rand KG2 gas-turbine product line.

Ener-Core, Inc. (ENCR), closed Wednesday's trading session at $0.182, up 1.11%, on 5,242,758 volume with 747 trades. The average volume for the last 60 days is 498,533 and the stock's 52-week low/high is $0.0741/$1.54.

Nutrastar International, Inc. (NUIN)

Zacks, FeedBlitz, and SmallCapVoice reported previously on Nutrastar International, Inc. (NUIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nutrastar International, Inc. is a leading producer and supplier of premium branded consumer products. The products include commercially cultivated Cordyceps Militaris, functional health beverages, and organic and specialty foods. The Company’s products sell throughout China through a sales and distribution network that covers over 10 provinces. Nutrastar International lists on the OTC Bulletin Board and the Company is based in Harbin, capital of Heilongjiang Province, China.

Cordyceps Militaris is one of the most highly regarded herbal nutrients in Traditional Chinese Medicine (TCM). Nutrastar International has developed and patented a cultivation process for Cordyceps. Therefore, this makes it the only company that can produce the natural herb on a mass commercial scale. Nutrastar is the largest producer of this ingredient. In addition, the Company is one of the largest wholesale distributors of organic and specialty foods in Heilongjiang Province.

Cordyceps Militaris is a premium TCM consumer product. It is derived from a fungus usually found in high altitude mountainous regions. The natural form of Cordyceps is a highly-valuable ingredient used in TCM and pharmaceutical products.

Regarding functional health drinks, Nutrastar produces and sells an array of these products containing Cordyceps Militaris. The design of the Cordyceps drink is to help fight fatigue and promote the health of the liver and kidneys. Furthermore, concerning organic and specialty foods, the Company, via its indirect subsidiary, Harbin Shuayi, acts as either a sales agent or distributor to market and sell organic and specialty food products supplied by third-party producers including Northeast Peculiar Rice.

Last week, Nutrastar International announced its results for the three months and nine months ended September 30, 2014. Selected financial highlights for the three months ended September 30, 2014 include net revenue of $11.16 million. This represents an increase of $0.22 million or 2.1 percent from $10.94 million in the comparable 2013 three month period. Gross profit was $8.99 million, representing a gross margin of 80.5 percent, and net income was $6.06 million, representing a net margin of 54.3 percent.

Nutrastar International, Inc. (NUIN), closed Wednesday's trading session at $1.75, even for the day, on 20,845 volume with 10 trades. The average volume for the last 60 days is 6,937 and the stock's 52-week low/high is $1.30/$3.95.

PURE Bioscience, Inc. (PURE)

SmarTrend Newsletters, Zacks, Wallstreetlivechat, and MissionIR reported earlier on PURE Bioscience, Inc. (PURE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PURE Bioscience, Inc. develops and markets technology-based bioscience products, which provide solutions to many worldwide health challenges. These include Staph (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE)/NDM-1+. The Company is the creator of the patented silver dihydrogen citrate (SDC) antimicrobial. PURE Bioscience is based in El Cajon, California. The Company’s shares trade on the OTC Markets’ OTCQB.

PURE Bioscience's proprietary high efficacy/low toxicity bioscience technologies (including the silver dihydrogen citrate-based antimicrobials) represent pioneering advances in different markets and lead today's global trend toward industry and consumer use of "green" products. This is while providing competitive advantages in efficacy and safety.  

The Patented SDC is an electrolytically generated source of stabilized ionic silver. It formulates well with other compounds. The Company’s patented SDC is the first new antimicrobial in decades. SDC can serve as the foundation for a wide variety of products in diverse markets. It is colorless, odorless, tasteless, and non-caustic. PURE produces and markets pre-formulated, ready-to-use product, and varying strengths of SDC concentrate as an additive or raw material for inclusion in other products.

PURE Bioscience's products include SDC-Based Hard Surface Disinfectant. SDC is the basis for the EPA registered hard surface disinfectant, PURE™ Hard Surface. SDC is highly toxic to bacteria, fungus and virus. It is non-toxic to humans and animals.

SDC kills microorganisms by way of two methods of action. The silver ion deactivates structural and metabolic membrane proteins leading to microbial death. The microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA. This stops the microbe's ability to replicate and leads to its death.

EPA-registered PURE™ Hard Surface disinfectant and food contact surface sanitizer provides a combination of high efficacy and low toxicity. It features 30-second bacterial kill times and 24-hour residual protection.

PURE Bioscience is executing its sales rollout plan with Subway®. The efficacy and environmental friendliness of PURE Hard Surface have been validated by SUBWAY® Restaurants. The product has recently been approved for use in SUBWAY®'s close to 27,000 franchised stores in the United States.

PURE Bioscience, Inc. (PURE), closed Wednesday's trading session at $0.58, down 6.45%, on 57,597 volume with 37 trades. The average volume for the last 60 days is 73,778 and the stock's 52-week low/high is $0.475/$1.57.

Arch Therapeutics, Inc. (ARTH)

Wall Street Resources reported this week on Arch Therapeutics, Inc. (ARTH), SmallCapVoice did earlier, and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTC BB-listed Arch Therapeutics, Inc. is a medical device company based in Wellesley, Massachusetts. It is developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch’s goal is to develop and commercialize products based on its pioneering technology platform, which makes surgery and interventional care faster and safer for patients.

The underlying technology, exclusively licensed from a leading university, supports an imaginative platform of smart materials that fulfill the criteria as a solution for a specialized field the Company calls, “stasis and barrier applications.” Arch Therapeutics’ flagship development stage product candidate is known as AC5™ (AC5 Surgical Hemostatic Device™). This is a synthetic peptide consisting of naturally occurring amino acids.

AC5™ is undergoing design to sophisticatedly achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures. Its solution smartly controls the movement of fluids and substances. AC5™ stops bleeding fast. AC5™ conforms to irregular wound geometry and assists in maintaining a clear field of vision directly into the wound area.

AC5™, when squirted or sprayed onto a wound, rapidly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances (including blood and other bodily fluids) regardless of kind of surgery or, based on early data, clotting ability, and healing occurs normally.

The Company indicates that in preclinical tests, AC5™ has been simple, effective, and versatile. So far, biocompatibility has been excellent and healing of tissue treated with the device has been normal.

Yesterday, Arch Therapeutics announced that an independent third party obtained positive data from a preclinical study assessing the use of AC5™ in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, (currently marketed under the brand name Brilinta®). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin. Another preclinical study reported like results regarding the antiplatelet medications Plavix® (clopidogrel) and aspirin when used individually and in combination.

Arch Therapeutics, Inc. (ARTH), closed Wednesday's trading session at $0.22, up 4.76%, on 323,883 volume with 95 trades. The average volume for the last 60 days is 115,144 and the stock's 52-week low/high is $0.15/$0.454.

MEDL Mobile Holdings, Inc. (MEDL)

TheMicrocapNews reported earlier on MEDL Mobile Holdings, Inc. (MEDL), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

MEDL Mobile Holdings, Inc. develops, acquires and publishes a growing library of mobile applications (apps). These apps perform particular functions for the user on the Apple and Android platforms. The Company is establishing a business model in which it expects to generate multiple revenue streams. These streams include development fees, download and in-app purchases, advertising, sponsorship, and licensing of technology. MEDL Mobile Holdings’ has its corporate headquarters in Fountain Valley, California.

MEDL Mobile's Software Development Kit (SDK) consists of an expanding collection of tools that have been designed to help developers to better market and monetize mobile applications. The Company has joined forces with Specific Media to supply mobile video advertising for MEDL Mobile's previously launched social media platform, "Hang w/." The Hang w/ platform enables live real-time video to be broadcast from one phone to many.

Broadcasters earn a percentage of the advertising revenue generated based upon the number of followers who are "Hanging w/" them. Anyone with an iPhone or Android device can connect immediately to an enormous base of fans via live-streaming video broadcasts.

The agreement gives Specific Media the exclusive rights to sell all unfilled advertising on the platform. MEDL Mobile Holdings retains the rights to collaborate directly with brands and advertising agencies to sell advertising and sponsorship for individual celebrities and for Hang w/ "channels" of content. MEDL is the largest shareholder of Hang With, Inc.

In October, MEDL Mobile announced that it signed a non-binding Letter of Intent (LOI) to sell its Custom Development Division to BBK Holdings. Mr. Andrew Maltin, MEDL Mobile CEO, said, "For MEDL, this move is a clear win for all parties involved. Our Custom Development Division finds a home in BBK, a larger, tech-focused, healthcare marketing powerhouse, where its growth can accelerate. MEDL Holdings would receive immediate operating capital and the opportunity for an ongoing revenue stream. And Hang w/ can move forward with the full resources and efforts of the parent company, focused on building the greatest live social video platform on the planet."

Yesterday, Hang w/announced that Google Lunar X PRIZE Competitor, Team Synergy Moon, will use the live-streaming video social media platform to bring viewers along on its journey to soft-land a planetary rover on the Moon. Synergy Moon's technological innovations aim to make manned space travel, personal satellite launches, and Solar System exploration cost-effective, and possible for everyone. The $30 million Google Lunar X PRIZE is a global competition. It challenges and inspires engineers and entrepreneurs worldwide to develop low-cost methods of robotic space exploration.

MEDL Mobile Holdings, Inc. (MEDL), closed Wednesday's trading session at $0.135, up 3.85%, on 132,484 volume with 21 trades. The average volume for the last 60 days is 91,180 and the stock's 52-week low/high is $0.1011/$0.48.

Nuvilex, Inc. (NVLX)

Stock Market Media Group, PennyStocks24, OTCJournal, and SmallCapVoice reported on Nuvilex, Inc. (NVLX), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Nuvilex, Inc. is a clinical-stage, global biotechnology company that lists on the OTCQB.  It provides cell and gene therapy solutions for the treatment of deadly diseases. The Company is concentrating on developing and preparing to commercialize treatments for cancer, diabetes, and other diseases founded on the live, therapeutically valuable, encapsulated cells platform. Nuvilex is leveraging its cancer biology and clinical oncology research experience and expertise, especially for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. The Company is based in Silver Spring, Maryland.

Nuvilex is focusing on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology called Cell-in-a-Box®. This unique technology will be used as a platform upon which treatments for a number of types of cancer (including advanced, inoperable pancreatic cancer) and diabetes are being built. The Company’s treatment for pancreatic cancer involves the use of the extensively used anticancer prodrug ifosfamide in tandem with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form.

Nuvilex's subsidiary is Medical Marijuana Sciences, Inc. Medical Marijuana Sciences’ dedication is to the development of cancer treatments based upon chemical constituents of marijuana - called cannabinoids. To do so, Nuvilex will examine ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids against cancers. This is while minimizing or outright eliminating the debilitating side effects normally associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers.

Nuvilex has completed the required preliminary steps to start a Phase 2b clinical trial of its pancreatic cancer treatment that it expects to begin in Q1 2015. Its treatment (Cell-in-a-Box®plus ifosfamide) will be compared one-on-one with the best available therapy (presently Abraxane® plus gemcitabine) for advanced, inoperable pancreatic cancer.

Earlier this month, Nuvilex announced that it submitted, via its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration (FDA) and the European Medicines Agency in the European Union. Like those in the United States (7 years) and the European Union (10 years), granting of the Orphan Drug Designation carries with it a considerable period of marketing exclusivity. This period is 5 years in Australia.

Today, Briefing.com reported that Nuvilex announced preliminary data from the preclinical study of effects of the Company’s pancreatic cancer treatment on Ascites Fluid Formation. It produced a significant survival advantage versus non-treated control animals. Nuvilex announced that promising preliminary data has been released from the preclinical animal study on the effects of its’ pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. The final data analysis will be released in the future.

Nuvilex, Inc. (NVLX), closed Wednesday's trading session at $0.234, up 14.71%, on 1,650,096 volume with 355 trades. The average volume for the last 60 days is 1,622,296 and the stock's 52-week low/high is $0.0201/$0.62.


The QualityStocks
Company Corner


WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.07, up 4.48%, on 75,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 43,663, and its 52-week low/high is $0.05/$0.26.

WordLogic Corp. was proud to announce today that the company, (www.twitter.com/wordlogiccorp), (www.facebook.com/wordlogiccorp), has released an iOS8 approved iKnowU keyboard with Reach technology in the Apple App Store. Users can log into their iPhone or iPad and download the keyboard for free within the next 10 days.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic (OTCQB:WLGC) Announces that Apple Approves the Launch of an iOS8 Version of the iKnowU Keyboard

WordLogic the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group

WordLogic Files Patent Infringement Lawsuit Against TouchType Ltd., Makers of SwiftKey

Pan Global Corp. (PGLO)

The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.015, up 20.00%, on 718,038 volume with 38 trades. The stock’s average daily volume over the past 60 days is 93,951, and its 52-week low/high is $0.009/$0.688.

Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.

The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.

Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.

Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer

Pan Global Corp. Company Blog

Pan Global Corp. News:

Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017

Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India

Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.39, up 30.00%, on 138,395 volume with 71 trades. The stock’s average daily volume over the past 60 days is 191,342, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device

Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace

Zenosense, Inc.; Protocol Design -- Lung Cancer Detection Tests

IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.44, up 8.64%, on 142,323 volume with 74 trades. The stock’s average daily volume over the past 60 days is 199,564, and its 52-week low/high is $0.0114/$0.62.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial, Inc. (IFAN) Announces Engagement of QualityStocks Investor Relations Services

IFAN Financial Acquires Mobile Payment Solutions Provider Mobicash America, Inc.

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0037, up 15.62%, on 199,263 volume with 12 trades. The stock’s average daily volume over the past 60 days is 1,519,200, and its 52-week low/high is $0.0021/$2.2308.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project Announces First Order From Walmart

The One World Doll Project Announces Financing Relationship With New York Hedge Fund, Blackbridge Capital

One World Holdings, Inc. Announces Engagement of QualityStocks Investor Relations Services

WRIT Media Group, Inc. (WRIT)

The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.02, up 33.33%, on 5,004 volume with 2 trades. The stock’s average daily volume over the past 60 days is 51,438, and its 52-week low/high is $0.0107/$0.50.

WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer

WRIT Media Group, Inc. Company Blog

WRIT Media Group, Inc. News:

WRIT Media Group Announces Product Updates and NASCAR Event Recap

Retro Infinity Sponsors NASCAR Driver Carlos Contreras' Record-Breaking 99th Career Race

WRIT Media Group (WRIT) CEO Featured in Exclusive QualityStocks Interview

Cannabics Pharmaceuticals, Inc. (CNBX)

The QualityStocks Daily Newsletter would like to spotlight Cannabics Pharmaceuticals, Inc. (CNBX). Today, Cannabics Pharmaceuticals, Inc. closed trading at $0.28, up 3.70%, on 3,889 volume with 3 trades. The stock’s average daily volume over the past 60 days is 8,197, and its 52-week low/high is $0.03/$1.40.

Cannabics Pharmaceuticals, Inc. (CNBX) was founded in 2012 by a team of experts in the fields of molecular biology, cancer research and pharmacology, who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.

Leveraging this expertise and knowledge, Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, contains a pure concentrate of cannabinoids derived from select cannabis strains, embedded in a sophisticated formulation which provides beneficial therapeutic effects for 10-12 hours upon a single oral administration.

The excipients of the proprietary Cannabics SR formulation are all certified food-grade ingredients and are free of artificial additives or chemical substances. Cannabics’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.

Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in business and pharmaceutical development, strategic consulting, venture capital, evolutionary and environmental sciences, anti-cancer drug development and molecular biology. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure. Disclaimer

Cannabics Pharmaceuticals, Inc. Company Blog

Cannabics Pharmaceuticals, Inc. News:

Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain

Cannabics Pharmaceuticals, Inc. (CNBX) Receives Cannabinoid R&D Lab Certification in Israel

Cannabics Pharmaceuticals, Inc. (CNBX) Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Wall Street Resources


Damn Good Penny Picks



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251